Scinai Secures $2M Equity Commitment
Ticker: SCNI · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: funding, equity, shareholder-agreement
TL;DR
Scinai gets $2M equity boost from its biggest shareholder.
AI Summary
On August 20, 2024, Scinai Immunotherapeutics Ltd. announced a $2 million private equity commitment agreement with its largest existing shareholder. This agreement aims to provide additional funding for the company's operations and development initiatives.
Why It Matters
This funding infusion from a major shareholder could provide Scinai Immunotherapeutics with crucial capital to advance its pipeline and operational goals.
Risk Assessment
Risk Level: medium — While the commitment is from a major shareholder, the amount is relatively small for a biotech company, and further funding may still be required.
Key Numbers
- $2.0M — Private Equity Commitment (Funding secured from largest shareholder)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- $2 million (dollar_amount) — Amount of private equity commitment
- August 20, 2024 (date) — Date of the press release and agreement
- largest existing shareholder (person) — Party providing the equity commitment
FAQ
What is the purpose of the $2 million private equity commitment?
The filing states that the commitment is an agreement entered into by Scinai Immunotherapeutics Ltd. with its largest existing shareholder, but does not specify the exact use of funds beyond general operational and development initiatives.
Who is the largest existing shareholder providing the commitment?
The filing identifies the party as 'its largest existing shareholder' but does not disclose the specific name of the shareholder.
When was this private equity commitment agreement announced?
The agreement was announced on August 20, 2024, via a press release.
What form type is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Has Scinai Immunotherapeutics Ltd. previously operated under a different name?
Yes, the company was formerly known as BiondVax Pharmaceuticals Ltd., with a name change date of June 24, 2014.
Filing Stats: 258 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-08-20 11:08:01
Key Financial Figures
- $2 million — ess release announcing its entry into a $2 million private equity commitment agreement wit
Filing Documents
- ea0211894-6k_scinai.htm (6-K) — 11KB
- ea021189401ex99-1_scinai.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 32KB
- 0001213900-24-070981.txt ( ) — 70KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 20, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2